Skip to content
DataLookout
Menu

ADAPTIVENCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 14 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Trial sites expanded: 30 → 33 locations
  2. Minor Trial sites expanded: 23 → 30 locationsv14
  3. Notable Primary completion pushed from Nov 2026 to Dec 2027v13 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 220 → 405 participants
    • Study completion pushed from Oct 2027 to Aug 2028
    • Trial arms changed: 4 → 9
    • Secondary endpoints revised (4)
    • Study description revised
    • Study sites revised (23)
  4. Minor Study sites: 21 to 23v12
  5. Minor Study sites: 20 to 21v11
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Study sites: 19 to 20v10
  2. Minor Study sites: 18 to 19v9
  3. Minor Study sites: 9 to 18v8
  4. Minor Study sites: 8 to 9v6
  5. Minor Study sites: 7 to 8v5
  6. Minor Study sites: 4 to 7v4
  7. Minor Study sites: 3 to 4v3
  8. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Jun 2025 to Jun 17, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean percent change from baseline in EASI at Week 24
Timeframe: Baseline, Week 24

Secondary (4)

Proportion of participants achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) and a ≥ 2-point reduction from baseline at Week 24
Proportion of participants achieving a ≥ 75% reduction in EASI (EASI-75) at Week 24
Proportion of participants achieving a ≥ 90% reduction in EASI (EASI-90) at Week 24
Incidence and severity of TEAE including treatment-emergent SAEs

Arms and interventions

IMG-007 Dose 1Experimental

Subcutaneous injection as per protocol.

IMG-007 Dose 2Experimental

Subcutaneous injection as per protocol.

IMG-007 Dose 3Experimental

Subcutaneous injection as per protocol.

IMG-007 Dose 4Experimental

Subcutaneous injection as per protocol.

IMG-007 Dose 5Experimental

Subcutaneous injection as per protocol.

IMG-007 Dose 6Experimental

Subcutaneous injection as per protocol.

IMG-007 Dose 7Experimental

Subcutaneous injection as per protocol.

Placebo Crossover Dose 1Placebo comparator

Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.

Placebo Crossover Dose 2Placebo comparator

Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.

Drugs: IMG-007, Placebo

Sites

33 sites in 4 countries

United States 16, Australia 8, Canada 7, New Zealand 2